AMPK signaling: a targetable tumor suppressor pathway?
Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, Baltimore, MD, USA. ASchneider@umaryland.edu
Abraham
A
Schneider
Ronald B
RB
Gartenhaus
D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology* / Q000378:metabolism; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000378:metabolism; D008687:Metformin / Q000494:pharmacology*; D058990:Molecular Targeted Therapy / Q000379:methods; D012265:Ribonucleotides / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects
D012265:Ribonucleotides; D000620:Aminoimidazole Carboxamide; D008687:Metformin; D055372:AMP-Activated Protein Kinases; C031143:AICA ribonucleotide